Regulatory News In Brief
This article was originally published in The Tan Sheet
Caffeine claims for avitae cross the line; Essiac Tea in hot water with FDA; studies are claims for Nature’s Pearl supplement; “Statin Support” label makes CoQ10 a drug; more Regulatory News In Brief.
You may also be interested in...
FDA fires warning shot on Breathable Foods’ “inhalable caffeine”; agency guidance advises against phthalate excipients in drugs; pandemic adverse event reporting guidance finalized; Globe All Wellness recall of tainted supplements is insufficient; more Regulatory News In Brief.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker